RevvityRVTYEarnings & Financial Report
Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.
Revenue
$649.9M
Gross Profit
$355.0M
Operating Profit
$44.1M
Net Profit
$26.0M
Gross Margin
54.6%
Operating Margin
6.8%
Net Margin
4.0%
YoY Growth
485.5%
EPS
$0.21
Revvity Q1 FY2024 Financial Summary
Revvity reported revenue of $649.9M (up 485.5% YoY) for Q1 FY2024, with a net profit of $26.0M (down 79.6% YoY) (4.0% margin). Cost of goods sold was $294.9M, operating expenses totaled $310.9M.
Key Financial Metrics
| Total Revenue | $649.9M |
|---|---|
| Net Profit | $26.0M |
| Gross Margin | 54.6% |
| Operating Margin | 6.8% |
| Report Period | Q1 FY2024 |
Revenue Breakdown
Revvity Q1 FY2024 revenue of $649.9M breaks down across 6 segments, led by Life Sciences Reagents at $177.2M (27.3% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Life Sciences Reagents | $177.2M | 27.3% |
| Immunodiagnostics | $175.6M | 27.0% |
| Reproductive Health | $123.9M | 19.1% |
| Services | $84.2M | 13.0% |
| Applied Genomics | $47.4M | 7.3% |
| Life Sciences Software | $44.9M | 6.9% |
Revvity Revenue by Segment — Quarterly Trend
Revvity revenue by segment across the last 4 reported quarters, showing how each business line (such as Life Sciences Reagents and Immunodiagnostics) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Immunodiagnostics | $240.8M | $212.7M | $218.8M | $197.6M |
| Reproductive Health | $149.3M | — | $135.6M | $126.8M |
| Services | — | — | $109.6M | $102.1M |
Revvity Annual Revenue by Year
Revvity annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.9B).
| Year | Annual Revenue |
|---|---|
| 2025 | $2.9B |
| 2024 | $2.8B |
| 2022 | $3.3B |
Revvity Quarterly Revenue & Net Profit History
Revvity results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $772.1M | +5.9% | $98.4M | 12.7% |
| Q3 FY2025 | $698.9M | +2.2% | $46.7M | 6.7% |
| Q2 FY2025 | $720.3M | +4.1% | $53.9M | 7.5% |
| Q1 FY2025 | $664.8M | +2.3% | $42.2M | 6.4% |
| Q4 FY2024 | $729.4M | +8.7% | $94.6M | 13.0% |
| Q3 FY2024 | $684.0M | -3.5% | $94.4M | 13.8% |
| Q2 FY2024 | $691.7M | +2.5% | $55.4M | 8.0% |
| Q1 FY2024 | $649.9M | +485.5% | $26.0M | 4.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $649.9M | $691.7M | $684.0M | $729.4M | $664.8M | $720.3M | $698.9M | $772.1M |
| YoY Growth | 485.5% | 2.5% | -3.5% | 8.7% | 2.3% | 4.1% | 2.2% | 5.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $13.43B | $13.42B | $12.77B | $12.39B | $12.36B | $12.36B | $12.14B | $12.17B |
| Liabilities | $5.59B | $5.55B | $4.85B | $4.73B | $4.72B | $4.81B | $4.76B | $4.92B |
| Equity | $7.85B | $7.87B | $7.92B | $7.67B | $7.64B | $7.56B | $7.38B | $7.25B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $147.6M | $158.6M | $147.9M | $174.2M | $128.2M | $134.3M | $138.5M | $182.0M |